← Back to patent-cliff list
Empagliflozin/Sitagliptin Hydrochloride
Tier C — Watch / tradeEmpagliflozin/Sitagliptin Hydrochloride
Daewon Pharmaceutical Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SGLT2, DPP4
Indications (approved)：Type 2 diabetes
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Empagliflozin/Sitagliptin Hydrochloride?
Approved indications include: Type 2 diabetes.
When does the Empagliflozin/Sitagliptin Hydrochloride patent expire?
No public expiry year is available for Empagliflozin/Sitagliptin Hydrochloride yet; this page updates once verified.
How do I get a quote for Empagliflozin/Sitagliptin Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03